Back
Science

Study Quantifies Educational and Career Impact of Atopic Dermatitis Across 27 Countries

Generated on: Last updated: 1 sources
View source

"AD is not merely a skin condition, but a chronic disease with lasting consequences on life trajectories." — Lead investigator Jonathan I. Silverberg

Atopic Dermatitis Limits Education and Career Choices, Global Study Finds

A major multinational study published in the Journal of Investigative Dermatology (JID) reveals that adults with atopic dermatitis (AD)—especially those who developed the condition in childhood—face significant, lasting limitations on their educational paths and professional lives.

Nearly a third of current AD patients report that their condition has directly limited their educational choices (27.9%) and career options (28.5%). For those with past AD, the figures are 25.6% and 26.5%, respectively, indicating the effects persist even after the skin clears.

Key Findings at a Glance

  • Social Avoidance: 41.3% of current patients avoid public contact, compared to 35.8% of past patients.
  • Environmental Adaptation: For those with childhood-onset AD, up to 43.5% had to adapt their living or working environment. This drops to 29.8% for those with adolescent-onset disease.
  • Persistent Stigma: Rates of workplace discrimination were similar between current and past patients, suggesting that the psychosocial impact of AD is long-lasting.
  • Global Disparities: Impact varies widely by region. India reported the highest burden, with 59.2% of patients saying AD limited their study choices. In contrast, Europe and Australasia reported the lowest rates, at 21%–23%.

Study Design

The research was conducted as a cross-sectional observational study from June to September 2024, part of the Scars of Life initiative. The analysis drew from 22,833 individuals across 27 countries on five continents, all with either current or past AD. Investigators used validated questionnaires to measure disease severity (POEM scale), psychosocial burden (ABS-A, PUSH-D), and demographic data.

Expert Commentary

Amy Paller, Section Editor of JID and a dermatologist at Northwestern University, stated that the data "create an imperative for early and aggressive treatment to achieve optimal control."

Co-lead investigator Laurent Misery (University of Brest) noted that regional differences likely reflect variation in disease awareness, healthcare access, and socioeconomic conditions.

Charles Taieb (EMMA), another co-lead investigator, emphasized the unseen cost: "AD leaves invisible scars... We must stop treating AD as merely a skin condition."

Delphine Kerob (La Roche-Posay) echoed this, stating the results confirm that the true burden of AD extends beyond the skin.

Investigator Recommendations

Based on the findings, the research team recommends the following actions:

  • Screening: Dermatologists and pediatricians should screen all AD patients for the disease's educational and professional impact.
  • Education: Programs such as "eczema schools" could help adolescents make more informed career choices.
  • Workplace Accommodations: Employers should consider accommodations for functional limitations caused by AD.
  • Policy Development: The team calls for the development of occupational health policies tailored specifically to AD patients.

"AD is not merely a skin condition... We must stop treating AD as merely a skin condition." — Co-lead investigator Charles Taieb